MC4MS provides funding and study research regarding
the impact of selected cannabinoids on fatigue, pain, spasticity, quality of life, immune response, CNS repair / demyelination and brain inflammation.
MC4MS is the first non-profit organization dedicated to the research and legalization of medical cannabis to treat multiple sclerosis.
It doesn’t have a high potential for abuse, and there are very legitimate medical applications. In fact, sometimes Marijuana is the only thing that works… It is irresponsible not to provide the best care we can as a medical community, care that could involve Marijuana. We have been terribly and systematically misled for nearly 70 years in the United States, and I apologize for my own role in that.
I have found in my study of these patients that Cannabis is really a safe, effective and non-toxic alternative to many standard medications.
The evidence is overwhelming that Marijuana can relieve certain types of pain, nausea, vomiting and other symptoms caused by such illnesses as multiple sclerosis, cancer and AIDS or by the harsh drugs sometimes used to treat them. And it can do so with remarkable safety. Indeed, Marijuana is less toxic than many of the drugs that physicians prescribe every day.
Yes... this plant, extracted with the correct terpenes, can alleviate MS symptoms.
Who we are
Medical Cannabis for Multiple Sclerosis - MC4MS
MC4MS is a non-profit foundation that was created by a marketing industry entrepreneur who at 42 years of age was diagnosed with MS. Around the same time, I inadvertently found myself being thrown into the emerging cannabis industry, changing the focus of my existing marketing firm to specialize in this unique industry. Fate talks. I soon began to see the testimonial of the medicinal benefits of cannabis. Things happen for a reason. I married the two into MC4MS. We will beat this. We will walk. We will talk. We won't give up that easily. I believe there is power in the plant. In certain CBD's, strains and terpenes. It's in the science. I'm Celeste Miranda. Welcome to MC4MS. Let's help find the future.
A few things cannabis does for multiple sclerosis
Sign up for
Sign up for our quarterly newsletter about MS and Cannabis therapies, including specific strains and terpenes.
This is what current research shows so far...
Cannabis could slow the neurodegenerative process of multiple sclerosis
Research findings suggest that cannabis could slow the neurodegenerative process of multiple sclerosis. Studies have shown that cannabinoids are involved in the regulation of the immune system by way of acting upon the cannabinoid receptors of the endocannabinoid system. Cannabinoids have shown they can modulate the inflammatory reaction and assist in neuroregeneration (Kubajewska & Constantinescu, 2010) (Croxford, et al., 2008). In one study, cannabinoids demonstrated neuroprotective effects during an animal model of multiple sclerosis, reducing the damage to myelin caused from inflammation (Pryce, et al., 2003). Another study found that cannabinoids administered to animals with a model of multiple sclerosis reduced neurological disability, improved motor coordination and limited the progression of the disease (de Lago, et al., 2012).
Cannabis can help multiple sclerosis patients manage the symptoms associated with their disease
Cannabis can help multiple sclerosis patients manage the symptoms associated with their disease. Cannabis has shown to be effective at reducing pain, muscle stiffness and spasms in multiple sclerosis patients (Koppel, et al., 2014) (Wade, et al., 2004). In one study, multiple sclerosis patients saw significant improvements in muscle spasticity and reduced sleep disturbances after four weeks of cannabis treatment (Novotna, et al., 2011). A similar study found that multiple sclerosis patients experienced pain and sleep improvements after five weeks of treatment with cannabis containing both THC and CBD (Rog, Nurmikko, Friede & Young, 2005). In a questionnaire, multiple sclerosis patients responded that cannabis was effective in improving spasticity, chronic pain of extremities, tremors, emotional dysfunctions, fatigue, double vision, bowel and bladder dysfunctions, dysfunctions of walking and balance and memory loss (Consroe, et al., 1997).
Clinical and anecdotal reports of cannabinoids' ability to reduce MS-related symptoms
Clinical and anecdotal reports of cannabinoids' ability to reduce MS-related symptoms such as pain, spasticity, depression, fatigue, and incontinence are plentiful in the scientific literature.[1-12] Specifically, investigators at the University of California at San Diego reported in 2008 that inhaled cannabis significantly reduced objective measures of pain intensity and spasticity in patients with MS in a placebo-controlled, randomized clinical trial. They concluded that "smoked cannabis was superior to placebo in reducing spasticity and pain in patients with multiple sclerosis and provided some benefit beyond currently prescribed treatment." Inhaled cannabis yielded similar results in a 2012 randomized, placebo-controlled trial involving MS subjects who were unresponsive to conventional therapy. That study, published in the Journal of the Canadian Medical Association, concluded, "Smoked cannabis was superior to placebo in symptom and pain reduction in patients with treatment-resistant spasticity.
Significant neuroprotection" in an animal model of multiple sclerosis
Other studies suggest that cannabinoids may also inhibit MS progression in addition to providing symptom management. Writing in the July 2003 issue of the journal Brain, investigators at the University College of London's Institute of Neurology reported that administration of the synthetic cannabinoid agonist WIN 55,212-2 provided "significant neuroprotection" in an animal model of multiple sclerosis. "The results of this study are important because they suggest that in addition to symptom management, ... cannabis may also slow the neurodegenerative processes that ultimately lead to chronic disability in multiple sclerosis and probably other disease," researchers concluded. Spanish researchers in 2012 reported similar findings, documenting that "the treatment of EAE mice with the cannabinoid agonist WIN55,512-2 reduced their neurological disability and the progression of the disease.
Always a good mix
Send us a message
We would love to hear from you and support you just as much as you support us. Let's do this together.